At Thermo Fisher Scientific, we have developed advanced
next-generation sequencing solutions to address key challenges in the molecular analysis of hematologic malignancies.
Join us during the 64th ASH Annual Meeting and Exposition to learn how we can help simplify your path to answers in the study of myeloid and lymphoid cancers.
Visit us at booth #3542
Attend these scientific poster presentations to see how NGS is advancing hemato-oncology studies.
The Ion Torrent™ Genexus™ System is the first turnkey next-generation sequencing (NGS) solution that automates the end-to-end workflow from the biological specimen all the way to the final report and delivers results in as little as a single day.*
Thinking about how the Genexus System works and how it could fit into your lab?
In our virtual laboratory environment powered by augmented reality (AR) technology, you can see:
Dr. Bevan Tandon, MD (Director, Hematopathology and Molecular Pathology - Pathline Labs) will review ongoing research in his laboratory using the Oncomine Myeloid Assay GX, an NGS-based test capable of delivering results in just 1-2 days. He will also share his experience with the Oncomine Myeloid MRD Assay (RUO), a highly sensitive NGS test for measurable residual disease (MRD) assessment that can identify mutations occurring at very low frequencies. Dr. Tandon will share recent analytical data from his team and offer his perspective on the value of NGS in hematopathology studies.
